US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
JP2598116B2
(ja)
|
1988-12-28 |
1997-04-09 |
協和醗酵工業株式会社 |
新規物質dc113
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
US5187186A
(en)
|
1989-07-03 |
1993-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrroloindole derivatives
|
JP2510335B2
(ja)
|
1989-07-03 |
1996-06-26 |
協和醗酵工業株式会社 |
Dc―88a誘導体
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
EP0563475B1
(en)
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5994341A
(en)
|
1993-07-19 |
1999-11-30 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic Compositions and methods for the treatment of arthritis
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
DE69434136T2
(de)
|
1993-10-01 |
2005-12-01 |
Teikoku Hormone Mfg. Co., Ltd. |
Dolastatin-derivate
|
GB9320575D0
(en)
|
1993-10-06 |
1993-11-24 |
Amp Gmbh |
Coaxial connector having improved locking mechanism
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6548530B1
(en)
|
1995-10-03 |
2003-04-15 |
The Scripps Research Institute |
CBI analogs of CC-1065 and the duocarmycins
|
ES2206607T3
(es)
|
1995-11-17 |
2004-05-16 |
Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) |
Derivados de epotilones, preparacion y utilizacion.
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US5969145A
(en)
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
US6680311B1
(en)
|
1996-08-30 |
2004-01-20 |
Eli Lilly And Company |
Cryptophycin compounds
|
AU716610B2
(en)
|
1996-08-30 |
2000-03-02 |
Novartis Ag |
Method for producing epothilones, and intermediate products obtained during the production process
|
PL188749B1
(pl)
|
1996-10-11 |
2005-04-29 |
Bristol Myers Squibb Co |
Zastosowanie przeciwciała anty-4-1BB i kompozycjaleku
|
BR9713363B1
(pt)
|
1996-11-18 |
2011-02-08 |
|
processo para preparação de epotilona d.
|
WO1999001124A1
(en)
|
1996-12-03 |
1999-01-14 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
CZ298027B6
(cs)
|
1997-02-25 |
2007-05-30 |
Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) |
Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu
|
CA2282504A1
(en)
|
1997-02-25 |
1998-08-27 |
Jun-Ping Xu |
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド |
免疫療法のctla−4結合ペプチド
|
US6117659A
(en)
|
1997-04-30 |
2000-09-12 |
Kosan Biosciences, Inc. |
Recombinant narbonolide polyketide synthase
|
WO1998056372A1
(en)
|
1997-06-09 |
1998-12-17 |
Massachusetts Institute Of Technology |
TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
AU8542898A
(en)
|
1997-07-16 |
1999-02-10 |
Schering Aktiengesellschaft |
Thiazole derivatives, method for their production and use
|
IL134419A0
(en)
|
1997-08-09 |
2001-04-30 |
Schering Ag |
Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
KR100574454B1
(ko)
|
1997-12-04 |
2006-04-27 |
브리스톨-마이어즈 스퀴브 컴페니 |
옥시라닐 에포틸론을 환원시켜 올레핀계 에포틸론을 제조하는 방법
|
US6096757A
(en)
|
1998-12-21 |
2000-08-01 |
Schering Corporation |
Method for treating proliferative diseases
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
US20020103136A1
(en)
|
1998-03-05 |
2002-08-01 |
Dong-Mei Feng |
Conjugates useful in the treatment of prostate cancer
|
WO1999061432A1
(en)
|
1998-05-12 |
1999-12-02 |
Biochem Pharma Inc. |
Fumagillin analogs and their use as angiogenesis inhibitors
|
US6121029A
(en)
|
1998-06-18 |
2000-09-19 |
Novartis Ag |
Genes for the biosynthesis of epothilones
|
US6603812B1
(en)
|
1998-08-17 |
2003-08-05 |
Linear Technology Corporation |
Hardware implementation of a decimating finite impulse response filter
|
GB2341689B
(en)
|
1998-09-08 |
2002-12-31 |
Ea Tech Ltd |
Locating underground power cable faults
|
CN1298851C
(zh)
|
1998-11-18 |
2007-02-07 |
牛津生物医学(英国)有限公司 |
多肽
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
MXPA01006422A
(es)
|
1998-12-23 |
2002-06-04 |
Pfizer Inc Abgenix Inc |
Anticuerpos monoclonales humanos de ctla-4.
|
US20080070981A1
(en)
|
2000-02-23 |
2008-03-20 |
Henryk Borowy-Borowski |
Water-soluble compositions of bioactive lipophilic compounds
|
KR100716074B1
(ko)
|
1999-06-17 |
2007-05-08 |
가부시키가이샤 히타치세이사쿠쇼 |
반도체 기억 장치 및 그 제조 방법
|
BR0013581A
(pt)
|
1999-08-23 |
2002-07-02 |
Dana Faber Cancer Inst Inc |
Pd-1, um receptor para b7-4, e usos para isto
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
DE19941311C1
(de)
|
1999-08-31 |
2001-06-07 |
Cryoelectra Ges Fuer Kryoelek |
Bandfilter
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
JP2003515323A
(ja)
|
1999-11-18 |
2003-05-07 |
オックスフォード バイオメディカ(ユーケイ)リミテッド |
抗 体
|
CA2388063C
(en)
|
1999-11-24 |
2010-06-08 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
WO2001049698A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
US7034121B2
(en)
|
2000-01-27 |
2006-04-25 |
Genetics Institue, Llc |
Antibodies against CTLA4
|
US6956036B1
(en)
|
2000-03-17 |
2005-10-18 |
Alcon, Inc. |
6-hydroxy-indazole derivatives for treating glaucoma
|
NZ553687A
(en)
|
2000-03-30 |
2010-03-26 |
Whitehead Biomedical Inst |
RNA sequence-specific mediators of RNA interference
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
JP5010089B2
(ja)
|
2000-09-19 |
2012-08-29 |
スピロジェン リミテッド |
Cc−1065およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法
|
US6747021B2
(en)
|
2000-10-02 |
2004-06-08 |
Eli Lilly And Company |
Cryptophycin compound
|
AU2002213248A1
(en)
|
2000-10-13 |
2002-04-22 |
The University Of Mississipi |
Synthesis of epothilones and relates analogs
|
SI1407044T2
(en)
|
2000-12-01 |
2018-03-30 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Small RNA molecules that mediate RNA interference
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US20040241745A1
(en)
|
2001-07-31 |
2004-12-02 |
Tasuku Honjo |
Substance specific to pd-1
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
US6534660B1
(en)
|
2002-04-05 |
2003-03-18 |
Immunogen, Inc. |
CC-1065 analog synthesis
|
JP2005529873A
(ja)
|
2002-04-12 |
2005-10-06 |
メダレックス インコーポレイテッド |
Ctla−4抗体を使用した治療の方法
|
US6596757B1
(en)
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
PT2206517T
(pt)
|
2002-07-03 |
2023-11-07 |
Tasuku Honjo |
Composições de imunopotenciação contendo anticorpos anti-pd-l1
|
EP1539237A4
(en)
|
2002-07-30 |
2006-05-24 |
Bristol Myers Squibb Co |
HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
|
EP1545613B9
(en)
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
PT3284753T
(pt)
|
2002-10-17 |
2020-05-04 |
Genmab As |
Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
ATE514713T1
(de)
|
2002-12-23 |
2011-07-15 |
Wyeth Llc |
Antikörper gegen pd-1 und ihre verwendung
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
WO2004078928A2
(en)
|
2003-02-28 |
2004-09-16 |
The Johns Hopkins University |
T cell regulation
|
US20060246123A1
(en)
|
2003-03-12 |
2006-11-02 |
Eli Gilboa |
Oligonucleotide mimetics
|
US20050250106A1
(en)
|
2003-04-24 |
2005-11-10 |
David Epstein |
Gene knock-down by intracellular expression of aptamers
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
CN107213469A
(zh)
|
2003-11-06 |
2017-09-29 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
KR100845354B1
(ko)
|
2004-03-26 |
2008-07-09 |
화이자 프로덕츠 인코포레이티드 |
항-ctla-4 항체의 용도
|
EP1781083A4
(en)
|
2004-06-18 |
2009-09-09 |
Univ California |
SEQUENCES OF BRASSICA INDEHISCENT1
|
US8239749B2
(en)
|
2004-06-25 |
2012-08-07 |
Apple Inc. |
Procedurally expressing graphic objects for web pages
|
EP1793858A4
(en)
|
2004-09-08 |
2008-12-10 |
Univ Ohio State Res Found |
HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
|
KR20070050956A
(ko)
|
2004-09-10 |
2007-05-16 |
와이어쓰 |
사람화 항-5t4 항체 및 항-5t4 항체/칼리케아미신 접합체
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
NZ601439A
(en)
|
2005-06-08 |
2012-11-30 |
Brigham & Womens Hospital |
Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
|
CA3201163A1
(en)
|
2005-07-01 |
2007-01-11 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
DK1994055T3
(da)
|
2006-03-10 |
2014-08-25 |
Wyeth Llc |
Anti-5t4-antistoffer og anvendelser deraf
|
AU2007241023B2
(en)
|
2006-03-30 |
2013-11-28 |
University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
US8367065B2
(en)
|
2006-09-15 |
2013-02-05 |
Enzon Pharmaceuticals, Inc. |
Targeted polymeric prodrugs containing multifunctional linkers
|
CA2662981A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Enzon Pharmaceuticals, Inc. |
Targeted polymeric prodrugs containing multifunctional linkers
|
NZ580132A
(en)
*
|
2007-03-14 |
2012-11-30 |
Endocyte Inc |
Binding ligand linked drug delivery conjugates of tubulysins to vitamins
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
ES2616355T3
(es)
|
2007-06-18 |
2017-06-12 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor humano de muerte programada PD-1
|
KR20090010580A
(ko)
|
2007-07-24 |
2009-01-30 |
조용식 |
페트용 토이렛
|
WO2009052623A1
(en)
|
2007-10-26 |
2009-04-30 |
Governing Council Of The University Of Toronto |
Therapeutic and diagnostic methods using tim-3
|
EP2240204A1
(en)
|
2008-02-04 |
2010-10-20 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
GB2457346B
(en)
|
2008-02-12 |
2012-03-28 |
Scott Cutters Uk Ltd |
Cutting tools
|
WO2009117531A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
US8460886B2
(en)
|
2008-07-04 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
CA2736816C
(en)
|
2008-09-12 |
2018-05-22 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
HRP20240240T1
(hr)
|
2008-12-09 |
2024-04-26 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille |
Pd−1抗体およびpd−l1抗体ならびにその使用
|
KR20120057588A
(ko)
|
2009-05-28 |
2012-06-05 |
메르사나 테라퓨틱스, 인코포레이티드 |
가변 속도 방출 링커를 포함하는 폴리알 약물 접합체
|
US8605955B2
(en)
|
2009-06-29 |
2013-12-10 |
DigitalOptics Corporation Europe Limited |
Methods and apparatuses for half-face detection
|
JP2013505944A
(ja)
|
2009-09-24 |
2013-02-21 |
シアトル ジェネティックス, インコーポレイテッド |
Dr5リガンド薬物結合体
|
JP5409275B2
(ja)
|
2009-11-06 |
2014-02-05 |
アズビル株式会社 |
監視制御システム
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
JP5920929B2
(ja)
|
2010-03-11 |
2016-05-18 |
ユセベ ファルマ ソシエテ アノニム |
Pd−1抗体
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
FR2963448A1
(fr)
|
2010-07-29 |
2012-02-03 |
Sagem Defense Securite |
Procede et systeme d'analyse de donnees de vol enregistrees au cours d'un vol d'un avion.
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
SG10201605401WA
(en)
|
2011-04-01 |
2016-08-30 |
Wyeth Llc |
Antibody-drug conjugates
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
US20130018499A1
(en)
|
2011-07-12 |
2013-01-17 |
The Boeing Company |
Producibility analysis during engineering design of composite parts
|
KR20190133790A
(ko)
|
2011-08-01 |
2019-12-03 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
CA2846432A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
CN113444165A
(zh)
|
2011-10-17 |
2021-09-28 |
Io生物技术公司 |
基于pd-l1的免疫疗法
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
EP2822957A1
(en)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
CN104736168B
(zh)
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
KR20210008155A
(ko)
|
2012-08-30 |
2021-01-20 |
암젠 인크 |
단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
|
KR20150070318A
(ko)
|
2012-10-16 |
2015-06-24 |
엔도사이트, 인코포레이티드 |
비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
NZ717668A
(en)
*
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
LT3129406T
(lt)
*
|
2014-04-11 |
2019-04-10 |
Medimmune, Llc |
Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
SG11201701128YA
(en)
*
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
AU2017234163B2
(en)
*
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
US11135307B2
(en)
*
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|